Clinical trial
A Phase 1b Trial of Lenvatinib Plus Nivolumab in Subjects With Hepatocellular Carcinoma
NCT03418922 is registered in ClinicalTrials.gov with Eisai Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b Trial of Lenvatinib Plus Nivolumab in Subjects With Hepatocellular Carcinoma
- Lead sponsor
- Eisai Co., Ltd.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 16, 2018
- Completion date
- December 28, 2022
- Enrollment
- 30 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.